Merrill rates ZymoGenetics at buy

ZymoGenetics, Inc. was rated at buy by Merrill Lynch analyst Hari Sambasivam after presentation of phase 3 data showing the statistically significant decrease in antibody formation to rhThrombin compared to bovine thrombin. In addition, the study met its primary endpoint of percentage of patients achieving hemostasis at 10 minutes. ZymoGenetic's rhThrombin was also found to have comparable efficacy to bovine thrombin. Shares of the Seattle-based pharmaceutical company were up 10 cents, or 0.57%, at $17.64. (Nasdaq: ZGEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.